论文信息 - Incidence of COVID-19 after vaccination in people with multiple sclerosis in Argentina: Data from the nationwide registry RelevarEM - 字舞流文

Incidence of COVID-19 after vaccination in people with multiple sclerosis in Argentina: Data from the nationwide registry RelevarEM

J. Correale | A. Carrá | E. Cristiano | N. Fernández Liguori | O. Garcea | G. Luetic | L. Patrucco | N. Deri | B. Silva | J. Rojas | M. Ysrraelit | R. Alonso | R. Piedrabuena | E. Carnero Contentti | P. López | M. Marrodan | C. Vrech | M. Balbuena | Emanuel Silva | M. Cabrera | J. Hryb | C. Mainella | S. Liwacki | S. Tizio | V. Tkachuk | M. Alonso Serena | M. Fiol | P. Nofal | Alejandra D. Martínez | M. Menichini | J. Steinberg | M. Casas | Jimena Míguez | F. Leguizamón | E. Knorre | G. Zanga | J. Viglione | S. Núñez | M. Burgos | Leila Cohen | A. Pappolla | M. Fracaro | A. Barboza | Patricio A. Blaya | D. Tavolini | Matías Kohler | L. Lázaro | Jorge Blanche | Gustavo Sgrilli | Pablo Divi | M. Jacobo | Débora Nadur | M. Parada Marcilla | L. Lazaro | Amelia Alves Pinheiro | Carolina Mainella | Darío Tavolini | Eduardo Knorre | A. Martínez | Marina Alonso Serena

[1] M. Ulivelli,et al. Breakthrough SARS-CoV-2 infections in MS patients on disease-modifying therapies , 2022, medRxiv.

[2] C. Agrati,et al. Humoral- and T-Cell–Specific Immune Responses to SARS-CoV-2 mRNA Vaccination in Patients With MS Using Different Disease-Modifying Therapies , 2021, Neurology.

[3] Jeffrey A. Cohen,et al. Clinical features and outcomes of COVID-19 despite SARS-CoV-2 vaccination in people with multiple sclerosis , 2021, Multiple sclerosis journal - experimental, translational and clinical.

[4] A. Carrá,et al. Evaluation of short-term safety of COVID-19 vaccines in patients with multiple sclerosis from Latin America , 2021, Multiple Sclerosis Journal - Experimental, Translational and Clinical.

[5] C. Rapôso,et al. Humoral and T-Cell Response to SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis Treated With Ocrelizumab. , 2021, JAMA neurology.

[6] M. Ulivelli,et al. Effect of SARS-CoV-2 mRNA vaccination in MS patients treated with disease modifying therapies , 2021, EBioMedicine.

[7] E. Havrdová,et al. Update on the management of multiple sclerosis during the COVID-19 pandemic and post pandemic: An international consensus statement , 2021, Journal of Neuroimmunology.

[8] A. Achiron,et al. COVID-19 vaccination in patients with multiple sclerosis: What we have learnt by February 2021 , 2021, Multiple Sclerosis Journal.

[9] G. Cutter,et al. Outcomes and Risk Factors Associated With SARS-CoV-2 Infection in a North American Registry of Patients With Multiple Sclerosis , 2021, JAMA neurology.

[10] A. Carrá,et al. COVID-19 in multiple sclerosis and neuromyelitis optica spectrum disorder patients in Latin America: COVID-19 in MS and NMOSD patients in LATAM. , 2021, Multiple sclerosis and related disorders.

[11] T. M. Belete. Review on Up-to-Date Status of Candidate Vaccines for COVID-19 Disease , 2021, Infection and drug resistance.

[12] P. Dormitzer,et al. COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses , 2020, Nature.

[13] U. Qazi,et al. COVID-19 Vaccine , 2020, Advances in Infectious Diseases.

[14] J. Correale,et al. Multiple sclerosis and neuromyelitis optica spectrum disorders in Argentina: comparing baseline data from the Argentinean MS Registry (RelevarEM) , 2020, Neurological Sciences.

[15] J. Correale,et al. The Argentinean multiple sclerosis registry (RelevarEM): Methodological aspects and directions. , 2019, Multiple sclerosis and related disorders.